During the last three decades Dr. Kocis has been involved in the drug discovery research in cancer, immunodeficiencies, CNS and asthma, and provided drug lead discovery leadership at Hoechst-Marion-Roussell, Zeneca Pharmaceuticals and AstraZeneca, most recently as the Global Head of AstraZeneca Discovery Capabilities & Sciences, Exploratory Chemistry. At AstraZeneca, Dr. Kocis built a global organization with the remit of generating proprietary chemotypes and building blocks, which contributed to the development of several clinical candidates including templates present in Iressa®, Zactima® and other medicines. Dr. Kocis also led the development of company-wide criteria for medicinally relevant compounds and the development of AstraZeneca compound profilers for research programs, clinical candidates and the corporate compound collection. Previously, at Zeneca Pharmaceuticals, he spearheaded modern medicinal chemistry together with the development of proprietary chemical technolo

 During the last three decades Dr. Kocis has been involved in the drug discovery research in cancer, immunodeficiencies, CNS and asthma, and provided drug lead discovery leadership at Hoechst-Marion-Roussell, Zeneca Pharmaceuticals and AstraZeneca, most recently as the Global Head of AstraZeneca Discovery Capabilities & Sciences, Exploratory Chemistry. At AstraZeneca, Dr. Kocis built a global organization with the remit of generating proprietary chemotypes and building blocks, which contributed to the development of several clinical candidates including templates present in Iressa®, Zactima® and other medicines. Dr. Kocis also led the development of company-wide criteria for medicinally relevant compounds and the development of AstraZeneca compound profilers for research programs, clinical candidates and the corporate compound collection. Previously, at Zeneca Pharmaceuticals, he spearheaded modern medicinal chemistry together with the development of proprietary chemical technolo